Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants

NCT00798304 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00798304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00798304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2009
Completion date
September 30, 2009
Enrollment
46 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

meningitis, meningococcal